Yes, O+ and O- can have a baby. The answer to Can O+ and O- Have a Baby? depends on Rh status, not O type alone. Both parents have group O blood, so the baby will be group O and ABO incompatibility is not the issue. The only pregnancy-specific risk is Rh incompatibility, which can occur when the mother is O negative and the fetus inherits Rh-positive blood from an O positive father. That risk is preventable with anti-D immune globulin, commonly called RhoGAM, given at about 28 weeks and within 72 hours after delivery when indicated. If the mother is O positive, her Rh status poses no anti-D risk.
Can O+ and O- Have a Baby? The ABO and Rh Mechanism
The ABO system is not the problem in an O+ and O- pairing. Both parents have group O blood, so neither can pass an A or B allele. The baby will be group O, and ABO hemolytic disease of the newborn is not created by this pair. In plain terms: the shared O type removes the usual ABO conflict before it starts.
The Rh system is the part that matters. Rh-positive red cells carry the RhD antigen; Rh-negative red cells lack it. If an O-negative mother carries an O-positive fetus, fetal red cells can enter her circulation. This can happen during pregnancy, delivery, miscarriage, abortion, trauma, or invasive procedures. As little as 0.1 mL of fetal blood can trigger sensitization in some women.
Once sensitized, the mother makes anti-D IgG antibodies. IgG crosses the placenta. In a later Rh-positive pregnancy, those antibodies can destroy fetal red cells and cause fetal anemia. The first sensitized pregnancy is often milder, but severity usually rises with each subsequent Rh-positive pregnancy. This is why prevention is timed before the immune system becomes fixed on the D antigen.
The O-positive father’s genotype controls the fetal chance. An O-positive father can be DD or Dd. A DD father passes D to every child, so every baby is Rh-positive. A Dd father passes D to about half of children and d to the other half. If the father is O negative, he passes only d, so the baby is Rh-negative and RhD incompatibility cannot occur.
When Rh Status Matters: A Parent-by-Parent Comparison
The parent pairings below show why “O+ and O-” alone is not a complete risk statement. The mother’s Rh status and the father’s Rh genotype matter more than the plus or minus sign on either parent’s report.
| Mother | Father | Baby’s O type | RhD incompatibility possible? | Key clinical point |
|---|---|---|---|---|
| O negative | O positive, DD | All O positive | Yes, all pregnancies | Anti-D at 28 weeks and after delivery when indicated |
| O negative | O positive, Dd | O negative or O positive, about 50/50 | Yes, about half of pregnancies | Fetal RhD testing can guide care; anti-D is still commonly used |
| O negative | O negative | All O negative | No | No anti-D for RhD unless another sensitizing event occurs |
| O positive | O negative | O positive or O negative | No anti-D risk to mother | Routine antibody screening still applies |
| O positive | O positive | O positive or O negative | No anti-D risk to mother | Baby may be O negative if both parents are Dd, but mother is Rh-positive |
| O positive | O positive, one DD | All O positive | No anti-D risk to mother | Rh status of baby does not create maternal anti-D risk |
The table’s central point is simple. An O-negative mother is the only parent in this pairing who can become sensitized to RhD. An O-positive mother does not make anti-D against a Rh-negative baby because she already carries the D antigen. In plain terms: the minus sign matters most when it belongs to the mother.
A confirmed O-negative father can lower the concern. If paternity is certain and the father is truly O negative, the fetus cannot be Rh-positive. Many clinicians still use standard prophylaxis when the father’s genotype is unknown, because a Dd O-positive father can pass d and produce an Rh-negative baby. The 50 percent and 100 percent figures above are genetic probabilities, not guarantees for a single pregnancy.
Quantifying the Real Risk: Rh, ABO, and Sensitization
Rh-negative status is not equally common in every population. In the United States, roughly 15 percent of White people, 8 percent of Black people, and 1 percent of Asian people are Rh-negative. Group O is common overall, so an O-negative mother with an O-positive partner is a routine clinical scenario, not a rare edge case.
Without prophylaxis, about 16 of 100 Rh-negative mothers exposed to Rh-positive fetal blood become sensitized. With timely anti-D immune globulin, that falls to roughly 1 in 1,000 or lower, per the American College of Obstetricians and Gynecologists 2017 guidance. The gap between those two numbers is the reason RhoGAM is one of the most successful prevention tools in obstetrics.
A standard 300 mcg dose of anti-D neutralizes about 15 mL of fetal red cells. That is equivalent to about 30 mL of fetal whole blood. A larger fetomaternal hemorrhage needs more anti-D, which is why clinicians may order a Kleihauer-Betke test or flow cytometry after trauma, abruption, or a complicated delivery. The 28-week and 72-hour postpartum doses are each standard 300 mcg; a 300 mcg dose covers about 15 mL of fetal red cells, or 30 mL of fetal whole blood, so a larger bleed needs extra dosing.
ABO incompatibility is a separate issue. It usually occurs when an O mother carries an A or B baby. Symptoms are often mild because A and B antibodies are mostly IgM and do not cross the placenta well. In an O+ and O- pairing, both parents are O, so the baby is O and this ABO mismatch does not arise. That is a corrected misconception worth stating plainly: O+ and O- do not create ABO incompatibility because there is no A or B allele to pass.
Timeline of Rh Prophylaxis in an O-Negative Pregnancy
Rh prevention is a schedule, not a single shot. The timeline below reflects common U.S. practice for an unsensitized O-negative mother. Exact timing can shift with bleeding, procedures, miscarriage, or access to fetal RhD testing.
| Timing | What happens | Why it matters |
|---|---|---|
| Preconception or first prenatal visit | Blood type, Rh status, and antibody screen | Identifies an O-negative mother and baseline anti-D status |
| About 10 to 12 weeks | Confirm pregnancy; antibody screen; optional cell-free DNA fetal RhD test | Early risk assessment when testing is available |
| 28 weeks | 300 mcg anti-D immune globulin if Rh-negative and unsensitized | Routine antenatal prophylaxis before most third-trimester bleeding risk |
| Any miscarriage, abortion, ectopic pregnancy, amniocentesis, CVS, trauma, or external cephalic version | Anti-D within 72 hours if Rh-negative and not sensitized | Prevents sensitization from procedure-related or pregnancy-related bleeding |
| Delivery | Cord blood for baby’s blood type and direct antiglobulin test | Determines whether postpartum anti-D is needed |
| Within 72 hours postpartum | 300 mcg anti-D if baby is Rh-positive and mother is unsensitized | Postpartum prophylaxis; larger doses if fetomaternal hemorrhage exceeds 30 mL whole blood |
| Future pregnancy | Antibody screen at first visit; middle cerebral artery Doppler if sensitized | Detects fetal anemia early and guides treatment |
The 72-hour window is not a suggestion. Anti-D works best when given soon after fetal Rh-positive blood enters the maternal circulation. If the window is missed, clinicians may still give anti-D, but protection is less certain. The 28-week dose and the postpartum dose are separate steps; one does not replace the other.
Variations, Edge Cases, and Misconceptions
An already sensitized O-negative mother needs a different plan. Anti-D immune globulin prevents sensitization; it does not treat existing anti-D antibodies. These pregnancies need early referral to maternal-fetal medicine. Middle cerebral artery peak systolic velocity monitoring often starts at about 16 to 18 weeks and repeats every 1 to 2 weeks. Severe fetal anemia may require intrauterine transfusion.
Weak D and partial D are uncommon but important. Some people type as Rh-positive on routine testing but carry a variant D antigen. A partial D variant can make anti-D after exposure to normal RhD-positive blood. Molecular testing may be needed to decide whether a person should be managed as Rh-negative. This is an area where expert guidance varies, so the blood bank and obstetric team should be involved.
Large fetomaternal hemorrhage changes dosing. A 300 mcg dose covers about 30 mL of fetal whole blood. A bleed larger than that needs additional anti-D based on quantified fetal red cells. The same logic applies to twins, abruption, manual removal of the placenta, and abdominal trauma. The standard dose is a floor, not a ceiling.
Several myths persist. O+ and O- parents do not have a “blood clash” that makes pregnancy impossible. An O-negative mother does not need to avoid an O-positive partner. RhoGAM is not a vaccine and does not alter the baby’s genes; it is an antibody preparation that clears D-positive fetal cells before the mother’s immune system responds. A first pregnancy is not automatically safe, because sensitization can begin during that pregnancy. A cesarean delivery does not prevent Rh sensitization, because bleeding can occur before delivery.
What to Actually Do Before and During Pregnancy
If you are asking Can O+ and O- Have a Baby? before pregnancy, start with blood type and antibody screening. An O-negative woman should know her Rh status and carry it in her prenatal record. If the father is O positive or his Rh genotype is unknown, assume the fetus could be Rh-positive until testing shows otherwise.
At the first prenatal visit, confirm the mother’s Rh status and antibody screen. Ask whether cell-free DNA fetal RhD testing is available and appropriate. If the mother is O negative and unsensitized, plan the 28-week anti-D dose. At delivery, ask for cord blood typing and a direct antiglobulin test. If the baby is Rh-positive, the mother needs anti-D within 72 hours unless she is already sensitized.
After any miscarriage, abortion, ectopic pregnancy, amniocentesis, chorionic villus sampling, abdominal trauma, or external cephalic version, ask about anti-D within 72 hours. Do not wait for bleeding to become heavy. If the mother is already sensitized, ask for maternal-fetal medicine referral and a plan for fetal anemia monitoring. In a future pregnancy, repeat the antibody screen at the first visit.
Seek urgent evaluation and ask for a RhoGAM review if any of these occur:
- Any vaginal bleeding or suspected miscarriage, even early in pregnancy
- A fall, car accident, or direct abdominal trauma during pregnancy
- Severe one-sided pelvic pain with dizziness, which may suggest ectopic pregnancy
- Passage of tissue or worsening pain after a positive pregnancy test
- An invasive procedure such as amniocentesis, chorionic villus sampling, or external cephalic version
Limitations of Rh Testing and Prophylaxis
Anti-D prophylaxis is highly effective, but it is not perfect. About 0.1 percent or fewer of treated Rh-negative women still become sensitized, often because of a missed dose, a large fetomaternal hemorrhage, or exposure before prophylaxis. The 16 percent untreated risk and the 0.1 percent treated risk are population estimates, not individual guarantees.
Cell-free DNA fetal RhD testing is promising but not universal. It can predict fetal RhD status with high accuracy after about 10 weeks, but false negatives and inconclusive results occur. Access, cost, and insurance coverage vary. Clinicians may still recommend standard anti-D when the fetal RhD result is unknown or the father’s genotype is uncertain.
The management of weak D and partial D remains evolving. Routine Rh typing does not capture every variant. Some guidelines treat weak D as Rh-positive, while partial D may need Rh-negative management. This is a genuine area of clinical uncertainty, not a settled rule. The established science is that anti-D prevents RhD alloimmunization; the unsettled science is how best to classify every rare RhD variant.